Several agonist antibodies targeting either DR4 or DR5 are currently in clinical development.26 Therefore, we next assessed the impact of antagonistic antibodies directed against DR4 or DR5 on the viability of myeloid leukemia cells treated with the Med+TRAIL combination. The gene discussed is TNFRSF10A; the disease is myeloid leukemia.